You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT JAMA
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 292 No. 2, July 14, 2004 TABLE OF CONTENTS
  JAMA
  •  Online Features
  Letters
 This Article
 •Full text
 •PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Contact me when this article is cited
 Related Content
 •Related articles
 •Similar articles in JAMA
 Topic Collections
 •Cardiovascular System
 •Cardiovascular Disease/ Myocardial Infarction
 •Alert me on articles by topic
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Risk-Treatment Paradox in Use of Statins

Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

To the Editor: Dr Ko and colleagues1 reported that the probability of receiving statin treatment actually decreases with increasing age and baseline risk for coronary heart disease. The authors defined baseline risk as the probability of death from any cause within 3 years. In high-risk older patients, death can be considered as a competing risk, and it has been recommended that limited life expectancy be factored into the creation of health care plans.2-3 Usually, death from cardiovascular disease is the most common form of an event that removes the risk of a different event. In this case, death from any cause can compete with the probability of benefit from statin therapy.

Ko et al reported 60% three-year mortality in their highest-risk subgroup. In the United States the average life expectancy of an individual who reaches the age of 95 years is still 3.6 years,4 suggesting that most high-risk older individuals . . . [Full Text of this Article]

Carlos O. Weiss, MD
cweiss9@jhmi.edu

Ravi Varadhan, PhD
Johns Hopkins Center on Aging and Health
Baltimore, Md



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

RELATED ARTICLES

Risk-Treatment Paradox in Use of Statins—Reply
Dennis T. Ko and David A. Alter
JAMA. 2004;292(2):169.
EXTRACT | FULL TEXT  

Lipid-Lowering Therapy With Statins in High-Risk Elderly Patients: The Treatment-Risk Paradox
Dennis T. Ko, Muhammad Mamdani, and David A. Alter
JAMA. 2004;291(15):1864-1870.
ABSTRACT | FULL TEXT  

Cancer Screening in Elderly Patients: A Framework for Individualized Decision Making
Louise C. Walter and Kenneth E. Covinsky
JAMA. 2001;285(21):2750-2756.
ABSTRACT | FULL TEXT  






HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2004 American Medical Association. All Rights Reserved.